Clinical Trials Logo

Lung Injury clinical trials

View clinical trials related to Lung Injury.

Filter by:

NCT ID: NCT05680831 Recruiting - Symptoms and Signs Clinical Trials

Pulmonary and Inflammatory Responses Following Exposure to a Low Concentration of Ozone or Clean Air

LOCONOZ2
Start date: October 13, 2022
Phase: Phase 1
Study type: Interventional

Purpose: The primary purpose of this study is to measure pulmonary function, symptoms, and pulmonary inflammatory responses in healthy young adults during and immediately after exposure to a low concentration of ozone (0.070 ppm) or clean air for 6.6 hours while undergoing moderate intermittent exercise. This concentration is the current EPA NAAQS standard for ozone.

NCT ID: NCT05647967 Recruiting - Clinical trials for Ultrasound Therapy; Complications

Features of Regional Perfusion of Lung Consolidation

Start date: January 1, 2022
Phase:
Study type: Observational

The aim of this study is to evaluate the potential usefulness of lung ultrasound to assess the size and perfusion of consolidation and explore their relationships with clinical outcome.

NCT ID: NCT05642832 Recruiting - Clinical trials for Respiratory Insufficiency

Feasibility of Reducing Respiratory Drive Using the Through-flow System

Throughflow
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

Mechanical ventilation can lead to diaphragm and lung injury. During mechanical ventilation, the diaphragm could be completely rested or it could be overworked, either of which may cause diaphragm injury. Mechanical stress and strain applied by mechanical ventilation or by the patient's own respiratory muscles can also cause injury to the lungs. Diaphragm and lung injury are associated with increased morbidity and mortality. Throughflow is a novel system that can reduce dead space without the need to increase the tidal ventilation, reducing the ventilatory demands and respiratory drive.

NCT ID: NCT05559970 Recruiting - Clinical trials for Mechanical Ventilation

Inhalational Sedation and Mechanical Power

Start date: November 15, 2022
Phase: N/A
Study type: Interventional

Analgosedation is usually given to critically ill patients admitted in ICU. Fentanyl is the most common agent used for this purpose. For sedative agent, midazolam and propofol are commonly administered. However, too much sedation is apparently associated with increased duration of mechanical ventilation, prolonged ICU stay, and increased mortality. In mechanically ventilated patients, mechanical power is the respiratory mechanic that can predict clinical outcomes including mortality in both ARDS and non-ARDS patients. Previous study demonstrated that sedating mechanically ventilated patients with propofol could decreased mechanical power. This was possibly associated with improved clinical outcomes in these patients. At present, there is no clinical study investigating effects of inhalation sedation on mechanical power and clinical outcomes in mechanically ventilated patients.

NCT ID: NCT05509088 Recruiting - Clinical trials for Traumatic Lung Injury

Impact of the Early Use of High Flow Nasal Cannula in Patients With Post-traumatic Lung Contusion, a Randomized Clinical Trial

Start date: July 28, 2022
Phase: N/A
Study type: Interventional

We hypothesize that early and continuous administration of oxygen via high flow nasal cannula in patients with lung contusion and non-severe acute lung injury might reduce the incidence of intubation and hold the deterioration of pulmonary functions.

NCT ID: NCT05414370 Recruiting - Acute Lung Injury Clinical Trials

Hyperoxia Induced Pulmonary Inflammation and Organ Injury: a Human in Vivo Model

Start date: December 2, 2022
Phase: N/A
Study type: Interventional

Oxygen is the most commonly administered therapy in critical illness. Accumulating evidence suggests that patients often achieve supra-physiological levels of oxygenation in the critical care environment. Furthermore, hyperoxia related complications following cardiac arrest, myocardial infarction and stroke have also been reported. The underlying mechanisms of hyperoxia mediated injury remain poorly understood and there are currently no human in vivo studies exploring the relationship between hyperoxia and direct pulmonary injury and inflammation as well as distant organ injury. The current trial is a mechanistic study designed to evaluate the effects of prolonged administration of high-flow oxygen (hyperoxia) on pulmonary and systemic inflammation. The study is a randomised, double-blind, placebo-controlled trial of high-flow nasal oxygen therapy versus matching placebo (synthetic medical air). We will also incorporate a model of acute lung injury induced by inhaled endotoxin (LPS) in healthy human volunteers. Healthy volunteers will undergo bronchoalveolar lavage (BAL) at 6 hours post-intervention to enable measurement of pulmonary and systemic markers of inflammation, oxidative stress and cellular injury.

NCT ID: NCT05408988 Recruiting - Clinical trials for Subarachnoid Hemorrhage

Neurogenic Myocardial and Lung Injury in SAH Patients

Start date: January 22, 2022
Phase:
Study type: Observational

Up to this day, little is known whether the extent of brain damage in patients with SAH correlates with the degree neurogenic myocardial injury and neurogenic lung injury. This is a prospective observational study designed to asses relationship between catecholamine surge and development of myocardial and lung injury in subarachnoid haemorrhage patients.

NCT ID: NCT05401474 Recruiting - Respiratory Failure Clinical Trials

Individualization Flow in Patients Treated With High Flow Nasal Therapy (iFLOW)

iFLOW
Start date: March 18, 2022
Phase: N/A
Study type: Interventional

In patients with acute hypoxemic respiratory failure (AHRF), High Flow Nasal Therapy (HFNT) improves oxygenation, tolerance, and decreases work of breathing as compared to standard oxygen therapy by facemask. The hypothesis is that this flow challenge (ROX index variation from 30 to 60L/min) could be used as a test for assessing changes in lung aeration, analyzed by the variation in end expiratory lung volume (ΔEELV), in patients treated with HFNC. It may allow to personalize the flow settings during HFNC. In this sense, an increase in EELV will be observed with higher flows in responders and, therefore, these participants may benefit from increasing the flow. In contrast, to increase the flow in non-responders (no significant increase in EELV with higher flows) increase the risk of patient self-inflicted lung injury (P-SILI).

NCT ID: NCT05364385 Recruiting - Acute Lung Injury Clinical Trials

Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease

STOPCLD
Start date: December 2, 2019
Phase: Phase 4
Study type: Interventional

Preterm infants are randomized to received either Intra-tracheal instillation of budesonide using surfactant as vehicle or a placebo. Intra-tracheal instillation of budesonide using surfactant as vehicle would facilitate its delivery to the periphery of the lung and would inhibit lung inflammation and mitigate acute lung injury.

NCT ID: NCT05316727 Recruiting - Acute Lung Injury Clinical Trials

Electronic Nicotine Delivery Devices and Potential Progression to Acute Lung Injury

ENDALI
Start date: November 15, 2021
Phase:
Study type: Observational

This is an observational - data and specimen collection study. There have been increasing reports of vaping-induced lung injury, including severe lung injury and rare cases of death. The mechanism by which vaping contributes to lung injury in susceptible persons is unknown, as is impact on chronic lung disease. The investigators aim to identify individuals with chronic electronic nicotine delivery device (ENDD) exposure and matched controls within our ongoing cohort of HIV+ and HIV-uninfected individuals, collect PFT data, bank respiratory and stool samples and collect clinical data for studies of clinical risk, inflammation, biomarkers, and the microbiome in the identification and modification of risk of progression to lung injury or chronic pulmonary disease.